The Therapeutics Goods Administration (TGA), Australia has ordered the urgent recall of pharmaceutical products manufactured by Pan Pharmaceuticals Limited (Australia) and suspended its licence following a series of safety and quality breaches on 28 April 2003. The breaches included substitution of ingredients, manipulation of test results and substandard manufacturing processes.
Pan Pharmaceuticals represents 70% of the Australian complementary pharmaceutical market. It also does contract manufacturing for many other brands, some of which are available locally.
 |
Actions taken by HSA
Due to the serious and widespread nature of the manufacturing problems identified by the TGA, HSA issued a press release on 28 April 2003 to advise the public to refrain from taking non-essential health products manufactured by Pan Pharmaceuticals.
To-date, 244 products marketed under 26 different brands in Singapore have been confirmed to be manufactured by Pan pharmaceuticals and all have been recalled from the market.
|
Other relevant information
The Pan Pharmaceuticals products subjected to recall affect those manufactured since 1 May 2002 as this was the latest date that the TGA could ensure that Pan complied with the requirements of good manufacturing practices.
|
Public advisory
Healthcare professionals are encouraged to report any suspected serious adverse drug reactions to vitamins and complementary medicines to the Pharmacovigilance (PV) Unit.
|
